Fenwick Represents Pharmakon in Loan Agreement with Immunocore

Fenwick represented Pharmakon, an investor in non-dilutive debt for the life sciences industry and the investment manager of the BioPharma Credit funds, in IP diligence regarding a loan agreement with Immunocore, a commercial-stage biotechnology company, providing Immunocore with up to $100 million committed.

The initial $50 million drawn from the credit facility will be used to refinance the Company's existing debt with Oxford Finance, LLC on improved terms and the remaining $50 million, if and when drawn, is intended to be used to support the continued development and commercialization of the Company’s pipeline and for other general purposes. More information can be obtained from Immunocore’s Third Quarter 2022 Financial Results.

The Fenwick team included corporate partner Eric Shedlosky and intellectual property partner Dr. Carl Morales and associate Dr. Hayan Yoon.